Work

[Advances in Radiotherapy for Extensive-stage Small Cell Lung Cancer in the Era of Immunotherapy].

Year: 2025

Type: review

Abstract: Small cell lung cancer (SCLC) is the thoracic malignant tumor and accounts for about 15% of lung malignancies and transfer often occurs by the time of diagnosis. Extensive stage-small cell lung cancer (ES-SCLC) accounts for about 2/3 of all SCLC. For many years, radiotherapy has occupied an important position in the treatment of SCLC, especially in the treatment of ES-SCLC, because SCLC is more sensitive to radiotherapy. However, in recent years, immune checkpoint inhibitor has shown more excellent antitumor activity in the treatment of ES-SCLC and become the mainstream argument for the treatment of ES-SCLC. However, will radiotherapy be buried by the times among the therapeutic approaches for ES-SCLC? In this article, we will review the clinical progress of radiotherapy, immunotherapy and combination therapy for ES-SCLC. .

Source: PubMed Central

DOI: 10.3779/j.issn.1009-3419.2025.102.20

Authors: Tingting Chen, Yanling Yang, Haonan Han, Dongmin Liu, Yajing Yuan, Liming Xu

Institutions: Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, China Three Gorges University

Language: Chinese

Topic: Lung Cancer Research Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Natural Science Foundation of China, Tianjin Medical University